Amazon bucked its usual tradition of having Prime Day in July. Prime Day 2026 is happening in June, kicking off in just a few weeks. Prime members will get access to many deals starting June 23rd at 3:01AM ET through June 27th at 3:01AM ET. As with Amazon’s previous events, you don’t need to be a Prime member to buy products during Prime Day, but there will likely be member-exclusive sales. Moreov...
Amazon bucked its usual tradition of having Prime Day in July. Prime Day 2026 is happening in June, kicking off in just a few weeks. Prime members will get access to many deals starting June 23rd at 3:01AM ET through June 27th at 3:01AM ET. As with Amazon’s previous events, you don’t need to be a Prime member to buy products during Prime Day, but there will likely be member-exclusive sales. Moreover, you’ll get fast shipping on purchases, access to Prime Video, plus other member benefits (like a few $5 pizzas and early access tickets to the new Spider-Man movie). The company has launched some early deals on its own tech products, including eero, Kindle, Echo, and other gadgets. We anticipate a lot more early deals to come over the next couple weeks leading into the event, and we’ll be sharing the best ones with you soon. We’ll also be highlighting deals happening at competing retailers, like Best Buy, Walmart, and more. An easy way to keep up with the latest deals you shouldn’t miss is by visiting The Verge , of course. We have some other free, convenient methods for those who prefer to catch up over email. Our Verge Shopping dispatch launches a few times each week, and serves as a roundup for good deals, as well as recent reviews and guides. You can sign up below. We’re also debuting Verge Shopping Deal Alerts , a daily newsletter that contains a deal we think is too good to miss (and might be sold out before you know it). It’s like breaking news, but for deals. It’s going to be a busy month full of deals (and developer conferences), so stay tuned for more.
Spark is Google’s new agentic answer for everything. According to every product demo from the last four years, planning a trip is a killer use case for AI. Just tell it where you're going, they all promise, and your chatbot / agent / other buzzword will exhaustively search travel options, read up on all the fun things to do, check all the local hotspots, and offer you a fully fledged itinerary. So...
Spark is Google’s new agentic answer for everything. According to every product demo from the last four years, planning a trip is a killer use case for AI. Just tell it where you're going, they all promise, and your chatbot / agent / other buzzword will exhaustively search travel options, read up on all the fun things to do, check all the local hotspots, and offer you a fully fledged itinerary. So far, I've found this to work only in the most generic ways: If you want to do the six most obvious things in any city on planet Earth, AI has you covered, but that's about as far as it goes. I had a very different experience using Spark, Google's new always-on AI agent . Spark is a hugely ambitious … Read the full story at The Verge.
The rapidly evolving landscape of Cloud AI has highlighted a significant challenge as the pace of AI technology advancements outstrips customers' ability to adopt them. According to Instruqt's 2026 State of Developer Adoption Report, conducted by SlashData, many software companies face operational hurdles, including team misalignment and maintaining content accuracy amid frequent product updates. ...
The rapidly evolving landscape of Cloud AI has highlighted a significant challenge as the pace of AI technology advancements outstrips customers' ability to adopt them. According to Instruqt's 2026 State of Developer Adoption Report, conducted by SlashData, many software companies face operational hurdles, including team misalignment and maintaining content accuracy amid frequent product updates. This gap in adoption is being addressed through innovative hands-on labs, which have proven...
Golden Cross Resources ( ZCRMF ) announced on Tuesday that it has increased the size of its previously announced non-brokered private placement as it now plans to raise gross proceeds of up to C$3.75M through the issuance of 22.06M units, which has been fully subscribed. The offering consists of units at a price of $0.17 per unit. Each unit will consist of one common share and one-half of one comm...
Golden Cross Resources ( ZCRMF ) announced on Tuesday that it has increased the size of its previously announced non-brokered private placement as it now plans to raise gross proceeds of up to C$3.75M through the issuance of 22.06M units, which has been fully subscribed. The offering consists of units at a price of $0.17 per unit. Each unit will consist of one common share and one-half of one common share purchase warrant. Each warrant will entitle the holder to purchase one additional share at a price of $0.30 per share for a period of two years from the closing of the offering. The company intends to use the proceeds of the offering for exploration drilling and development of the company's Reedy Creek high-grade gold project located in Victoria, Australia, and for general working capital and administrative purposes. Golden Cross may pay finder's fees on some portion of the gross proceeds of the offering to certain arms-length parties who assist the Company in introducing subscribers to the offering. The company highlighted that members of the company's management team may participate in the offering. More on Golden Cross Resources Inc. Financial information for Golden Cross Resources Inc.
UroGen Pharma ( URGN ) announced on Tuesday that it reached a settlement and license agreement with Teva Pharmaceuticals ( TEVA ) to resolve a patent dispute over its cancer therapy Jelmyto. The dispute arose after the Israeli drugmaker sought to market a generic version of Jelmyto, which is indicated in the U.S. for adults with low-grade upper tract urothelial cancer, a tumor of the urinary tract...
UroGen Pharma ( URGN ) announced on Tuesday that it reached a settlement and license agreement with Teva Pharmaceuticals ( TEVA ) to resolve a patent dispute over its cancer therapy Jelmyto. The dispute arose after the Israeli drugmaker sought to market a generic version of Jelmyto, which is indicated in the U.S. for adults with low-grade upper tract urothelial cancer, a tumor of the urinary tract. With regulatory exclusivity for Jelmyto through April 15, 2027, the company alleged that Teva ( TEVA ) submitted an Abbreviated New Drug Application to market its Jelmyto version before the expiry of relevant patents. As part of the settlement, Teva ( TEVA ) will receive a non-exclusive license from UroGen ( URGN ) to market its generic version beginning on September 15, 2030, subject to FDA approval. The parties will also request that the court dismiss the litigation with prejudice, meaning cases over similar claims cannot be refiled. More on UroGen Pharma, Teva Pharmaceutical Teva's Growth Story Is No Longer Just Generic, It's Getting Branded UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer Transcript UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript TrumpRx expands into generic medicines HHS officials considered banning SSRI antidepressants - report
MF3d/E+ via Getty Images Here's a number for you to keep in mind: 46 million+. That is the number of Edge AI SoCs that Ambarella Inc. ( AMBA ) has already cumulatively shipped to its various customers, and they are just getting started. These devices provide a significant advantage to their users over typical cloud AI devices because they process information in the space where it is generated. Thi...
MF3d/E+ via Getty Images Here's a number for you to keep in mind: 46 million+. That is the number of Edge AI SoCs that Ambarella Inc. ( AMBA ) has already cumulatively shipped to its various customers, and they are just getting started. These devices provide a significant advantage to their users over typical cloud AI devices because they process information in the space where it is generated. This helps to eliminate several issues that one could encounter with cloud AI devices, including: High bandwidth costs Latency issues Privacy concerns As more and more companies demand AI devices, they are increasingly focused on these types of issues, and Ambarella's devices help them to eliminate some of those concerns. Remember, a lot of the market is focused on AI data centers right now, and for good reasons, but there are other applications for AI that extend beyond those buildings. All the drones, robots, cameras, and other pieces of technology that many of us will come to rely on will require a certain measure of AI to keep them operational. Ambarella is one of just a handful of companies that fill that niche and can provide the infrastructure necessary to create that future. Revenue Acceleration is Beginning to Kick In It's one thing to have a vision for what your company can do, and it is something else entirely to watch that vision begin to pan out. I contend that Ambarella is in the latter half of that journey. They are beginning to see revenue acceleration as they put their strategic vision into play. During their most recent earnings report , the company reported revenues of $100.36M, a 16.87% YoY increase compared to the year prior. Even better than that, they also offered guidance of revenues between $105M and $111M for Q2. This type of guidance is music to a bullish investor's ears because it implies that the company is seeing revenue acceleration on multiple fronts, all at the same time. It may mean that customers are exploring an entire catalog of products th...
(Bloomberg) -- Elon Musk’s SpaceX is negotiating to pay razor-thin fees to Wall Street firms handling its IPO — but banks are still likely to rake in about $500 million from the record-setting market debut.Most Read from BloombergRussia Finance Officials Tell Putin War Spending Is UnaffordableCanada Dips Into Technical Recession for First Time Since 2020Alphabet to Raise $80 Billion in Equity for ...
(Bloomberg) -- Elon Musk’s SpaceX is negotiating to pay razor-thin fees to Wall Street firms handling its IPO — but banks are still likely to rake in about $500 million from the record-setting market debut.Most Read from BloombergRussia Finance Officials Tell Putin War Spending Is UnaffordableCanada Dips Into Technical Recession for First Time Since 2020Alphabet to Raise $80 Billion in Equity for AI SpendingAndrew Left Found Guilty in Case That Spooked Short SellersUS Says Deals With Iran for Sa
The Alkaline Water Company ( WTER ) on Tuesday signed a Letter of Intent to acquire Alberta -based bottling and canning company Eureka Beverages. "The proposed acquisition is expected to expand WTER's North American manufacturing footprint, strengthen its Canadian private label capabilities, and provide additional operational infrastructure to support future growth initiatives across multiple beve...
The Alkaline Water Company ( WTER ) on Tuesday signed a Letter of Intent to acquire Alberta -based bottling and canning company Eureka Beverages. "The proposed acquisition is expected to expand WTER's North American manufacturing footprint, strengthen its Canadian private label capabilities, and provide additional operational infrastructure to support future growth initiatives across multiple beverage categories," the company said. Under the terms of the LOI, the proposed purchase price consists of $1M in cash and C$6M in restricted WTER common stock. The cash consideration is expected to be paid in installments: $250,000 within 60 days following execution of a definitive agreement and the remaining balance payable in equal monthly installments beginning August 2026 over a nine-month period. Eureka focuses on private label beverage manufacturing and co-packing services. Press release More on Alkaline Water Historical earnings data for Alkaline Water Financial information for Alkaline Water
Maksym Isachenko Mesabi Metallics said late Monday it agreed to sell 50% of its royalty interest to The Metals Royalty Company ( TMCR ) for $265M, implying a valuation of more than $500M for the royalty platform. The transaction will be completed in two equal tranches of $132.5M each, with the first tranche closed on June 1 and the second tranche expected to close within 60 days. TMCR ( TMCR ) sai...
Maksym Isachenko Mesabi Metallics said late Monday it agreed to sell 50% of its royalty interest to The Metals Royalty Company ( TMCR ) for $265M, implying a valuation of more than $500M for the royalty platform. The transaction will be completed in two equal tranches of $132.5M each, with the first tranche closed on June 1 and the second tranche expected to close within 60 days. TMCR ( TMCR ) said the Mesabi Royalty will deliver a long-duration royalty stream that aligns with its investment mandate, with anticipated annual royalty cash flow potential of up to ~$13M; commissioning of the project is expected to begin in H2 2026, with the opportunity to double the cash flow, assuming the option to acquire an additional 1% royalty is completed. Once operational, Mesabi Metallics will become one of the only significant domestic producers of merchant DR-grade iron ore pellets in North America; the pellets are a critical input for electric arc furnace steelmaking, yet the U.S. relies heavily on imports from Brazil and elsewhere for supply. More on The Metals Royalty Company Financial information for The Metals Royalty Company